Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology Inc (NQ: VIR )

7.495 +0.375 (+5.27%)
Streaming Delayed Price Updated: 2:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates
Via Benzinga
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It
BARDA will pay Vir up to $1 billion to develop its experimental treatment. 
Via Investor's Business Daily
This Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts
Via Benzinga
Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment
Via Benzinga
Brii Biosciences Exercises Option For Vir Biotechnology's Hepatitis B Antibody In Greater China
Via Benzinga
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
From Vir Biotechnology, Inc.
Via GlobeNewswire
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Where Vir Biotechnology Stands With Analysts
Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
  Gainers   
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Vir Biotechnology Earnings Preview
  Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that Vir... 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. 
Via Benzinga
Earnings Preview: Vir Biotechnology
Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement. Analysts estimate that Vir... 
Via Benzinga
7 Undervalued Biotech Stocks to Buy Before They Boom
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier. 
Via Investor's Business Daily
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
From Axcella To Tonix, Here Are The Penny Stocks Of Companies Working On Long Covid
More than four in 10 people in a recent survey knew of someone with long Covid. 
Via Investor's Business Daily
Billionaire Bill Gates Is Betting Against TSLA Stock. Here’s Where He’s Putting His Money Instead.
Earlier this year, it was revealed that Bill Gates had a half a billion dollar short position against TSLA stock. So, what is he bullish on? 
Via InvestorPlace
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
Via Benzinga
10 Biggest Price Target Changes For Thursday
Wells Fargo cut the price target on Ford Motor Company (NYSE: F) from $24 to $12. Ford shares fell 2.8% to $12.47 in pre-market trading. 
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
What Defines a Value Stock? 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.